Ripertamab for chronic inflammatory demyelinating polyneuropathy
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an investigational drug called Ripertamab for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition causing weakness and numbness. The goal is to see if the drug can improve symptoms compared to no additional treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a confirmed diagnosis of CIDP using standard criteria
- Have at least moderate symptoms (as measured by INCAT score of 2 or higher)
- Be either on a stable dose of corticosteroids (≤10 mg/day) or IVIg/SCIg and willing to stop, OR have never been treated, OR have stopped these treatments at least 6 months ago
- Not have other causes of neuropathy, active infections (like hepatitis B, C, HIV), or certain cancers
- Use reliable birth control if you or your partner can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Ripertamab for people with neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the optic nerves and spinal cord. The drug aims to reduce relapses (flare-ups) of symptoms. It may be an option if you've had recent relapses despite current treatment.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
This trial tests a new medicine called ripertamab for children and young adults with nephrotic syndrome that keeps coming back or requires steroids. The goal is to see if it helps prevent relapses with fewer side effects.
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.